Neurocrine Bio. (NBIX) PT Raised to $135 at Barclays
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.13 -0.33%
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Rating Summary:
30 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Join SI Premium – FREE
Barclays raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $135.00 (from $100.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'
- Dyne Therapeutics (DYN) PT Lowered to $37 at Raymond James
- Hyperion DeFi, Inc. (HYPD) PT Raised to $8.45 at Chardan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
